Syndax Pharmaceuticals, Inc. (SNDX) — Analysis Summary
Syndax Pharmaceuticals, Inc. (SNDX) has a market cap of $1.69B with year-over-year revenue growth of +627.8%. Net margin stands at -165.6%. The stock trades at a P/E ratio of -6.9.
Key Takeaways
- Revenue changed +627.8% year-over-year
- Net margin of -165.6%
- P/E ratio of -6.9
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, SNDX posted revenue growth of +627.8% and trades at a P/E of -6.9.
Syndax Pharmaceuticals, Inc. (SNDX)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -55882.3x — earnings do not cover interest payments
D/E at 8.3x — extreme leverage
Operating margin at -102.9% — severe operating losses
Net margin at -112.0% — losses exceed revenue (possible one-time charges)
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
298
Headquarters
NEW YORK, NY
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.